Rhamnogalacturonan-I based microcapsules for targeted drug release
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Rhamnogalacturonan-I based microcapsules for targeted drug release. / Svagan, Anna J.; Kusic, Anja; De Gobba, Cristian; Larsen, Flemming Hofmann; Sassene, Philip; Zhou, Qi; Van De Weert, Marco; Mullertz, Anette; Jørgensen, Bodil; Ulvskov, Peter.
I: P L o S One, Bind 11, Nr. 12, e0168050, 2016.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Rhamnogalacturonan-I based microcapsules for targeted drug release
AU - Svagan, Anna J.
AU - Kusic, Anja
AU - De Gobba, Cristian
AU - Larsen, Flemming Hofmann
AU - Sassene, Philip
AU - Zhou, Qi
AU - Van De Weert, Marco
AU - Mullertz, Anette
AU - Jørgensen, Bodil
AU - Ulvskov, Peter
PY - 2016
Y1 - 2016
N2 - Drug targeting to the colon via the oral administration route for local treatment of e.g. inflammatory bowel disease and colonic cancer has several advantages such as needle-free administration and low infection risk. A new source for delivery is plant-polysaccharide based delivery platforms such as Rhamnogalacturonan-I (RG-I). In the gastro-intestinal tract the RG-I is only degraded by the action of the colonic microflora. For assessment of potential drug delivery properties, RG-I based microcapsules (~1 μm in diameter) were prepared by an interfacial poly-addition reaction. The cross-linked capsules were loaded with a fluorescent dye (model drug). The capsules showed negligible and very little in vitro release when subjected to media simulating gastric and intestinal fluids, respectively. However, upon exposure to a cocktail of commercial RG-I cleaving enzymes, ~ 9 times higher release was observed, demonstrating that the capsules can be opened by enzymatic degradation. The combined results suggest a potential platform for targeted drug delivery in the terminal gastro-intestinal tract.
AB - Drug targeting to the colon via the oral administration route for local treatment of e.g. inflammatory bowel disease and colonic cancer has several advantages such as needle-free administration and low infection risk. A new source for delivery is plant-polysaccharide based delivery platforms such as Rhamnogalacturonan-I (RG-I). In the gastro-intestinal tract the RG-I is only degraded by the action of the colonic microflora. For assessment of potential drug delivery properties, RG-I based microcapsules (~1 μm in diameter) were prepared by an interfacial poly-addition reaction. The cross-linked capsules were loaded with a fluorescent dye (model drug). The capsules showed negligible and very little in vitro release when subjected to media simulating gastric and intestinal fluids, respectively. However, upon exposure to a cocktail of commercial RG-I cleaving enzymes, ~ 9 times higher release was observed, demonstrating that the capsules can be opened by enzymatic degradation. The combined results suggest a potential platform for targeted drug delivery in the terminal gastro-intestinal tract.
U2 - 10.1371/journal.pone.0168050
DO - 10.1371/journal.pone.0168050
M3 - Journal article
C2 - 27992455
AN - SCOPUS:85006930226
VL - 11
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 12
M1 - e0168050
ER -
ID: 171545859